Pharmaceutical Investing Cerecor Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017
Pharmaceutical Investing Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3)
CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate
Eagle Pharmaceuticals Founder, President & CEO Scott Tarriff Named EY Entrepreneur Of The Year® 2016 New Jersey Region
Alpine Immune Sciences Announces $48 Million Series A Financing to Support Discovery and Development of the Next Generation of Immunotherapies
Cortice Biosciences Announces Presentation of Results from a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma at the Annual Meeting of the American Society of Clinical Oncology
Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French
AGTC Announces Data Evaluating Novel AAV-Based Gene Therapy as a Potential Treatment for Leber Congenital Amaurosis (LCA) and Severe Early-Childhood-Onset Retinal Degeneration (SECORD)
Amicus Therapeutics Receives Positive CHMP Opinion for Approval of Migalastat in Patients with Fabry Disease in European Union
175m @ 2.5% Copper from 7.6m, Hole Ends in 4.46% Copper & Open at Depth Danvers Drilling Delivers a Globally Significant Copper Intersection
